NCT05767736 - A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

10,500

Participants

Timeline

Start Date

June 8, 2024

Primary Completion Date

December 1, 2032

Study Completion Date

December 1, 2032

Conditions

Multiple Sclerosis

Interventions

DRUG

Diroximel Fumarate

Administered as specified in the treatment arm.

DRUG

Dimethyl Fumarate

Administered as specified in the treatment arm.

DRUG

Disease-Modifying Therapies (DMTs)

Administered as specified in the treatment arm.

Trial Locations (1)

Research Site, Cambridge